BOTHELL, Wash., May 27 CellCyte GeneticsCorporation (CellCyte) (OTC Bulletin Board: CCYG) today reaffirmed itscommitment to provide shareholders, potential investors and journalists withaccurate and up-to-date information by launching a comprehensive Investor Roompowered Web site: www.cellcyte.com . Shareholders, investors and journalistsseeking background information or sources for stories from CellCyte can accessthe information easily in the new Web site, which was designed to meet theirneeds quickly and efficiently.
CellCyte's Investor Room website includes corporate background materials,executive bios, SEC filings, stock charts, news releases, and links to newsand Web sites on stem cell research. The multimedia capabilities of theInvestor Room system will allow CellCyte to communicate in detail regardingits technology and development plans. Further, investors and journalists canopt-in to receive email alerts on news from CellCyte.
About CellCyte Genetics
CellCyte Genetics is a biotechnology company engaged in the discovery,development and commercialization of stem cell enabling therapeutic products.CellCyte is developing products designed to allow more efficient delivery andincreased retention of adult stem cells to diseased organs, such as the heart.The goal of these therapies is to increase the number of stem cells deliveredto a damaged organ, thereby markedly increasing organ healing and functionalrestoration. The Company's lead product in development, CCG-TH30, is designedto send autologous bone marrow-derived (adult) stem cells to the heart ofpatients after a heart attack.
For further information see: www.cellcyte.com .
Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.
SOURCE CellCyte Genetics Corporation